{"product_id":"supernus-bcg-matrix","title":"Supernus Pharmaceuticals Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eActionable Strategy Starts Here\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eSupernus Pharmaceuticals sits at an inflection point where branded CNS products and pipeline assets could be Stars or Question Marks depending on market uptake and patent trajectories; legacy drugs may act as Cash Cows funding R\u0026amp;D while underperformers risk becoming Dogs without strategic repricing or lifecycle management. This snapshot hints at allocation priorities and competitive pressures, but the full BCG Matrix delivers quadrant-by-quadrant placements, data-driven recommendations, and ready-to-use Word and Excel files—purchase now to turn this intelligence into decisive strategy.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eQelbree ADHD Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eQelbree remains a Star as it reached an estimated $420M US sales in 2025, capturing roughly 18% of the ADHD market and 22% of non-stimulant prescriptions across pediatric and adult cohorts.\u003c\/p\u003e\n\u003cp\u003eBy end-2025 its non-stimulant profile drove uptake from stimulant-preferring clinicians, supporting a year-over-year volume growth near 35% and reducing stimulant share in sampled clinics by ~4 ppt.\u003c\/p\u003e\n\u003cp\u003eSupernus increased Qelbree commercial spend to about $110M in 2025, funding marketing and physician education to sustain rapid market-share expansion.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGocovri Parkinson Market Leadership\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGocovri (amantadine) is a high-growth asset in Parkinson dyskinesia, reporting 2024 U.S. net sales of $222 million and growing ~18% YoY, driven by its unique dual indication for dyskinesia and OFF episodes that gives it clear clinical differentiation.\u003c\/p\u003e\n\u003cp\u003eSupernus has invested heavily in field resources—sales force +40% since 2022—helping Gocovri hold ~55% share of the specialty movement-disorder market and sustain premium pricing with average net price per prescription ≈ $3,800 in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSPN-830 Apomorphine Pump Launch\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHigh-growth: SPN-830 apomorphine infusion pump targets advanced Parkinsons (affecting ~1.2M US adults, 2024), entering a category forecasted to grow ~9.5% CAGR through 2030; device-led therapy addresses continuous motor-fluctuation treatment gaps where oral meds fail ~40% of patients.\u003c\/p\u003e\n\u003cp\u003eStar potential: as Supernus first-to-market pump, launch needs upfront R\u0026amp;D and capex (likely $150–250M program spend estimate), but could capture substantial share given limited direct competitors and pricing power in infusion clinics.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdult ADHD Segment Expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSupernus shifted marketing and R\u0026amp;D toward adults as adult ADHD prescriptions grew ~9% CAGR 2019–2024 versus pediatric ~3%, targeting a $4.2B US adult market by 2025 per IQVIA; Qelbree’s nonstimulant label and 7% share in adult newly treated patients helped Supernus raise adult revenue share to ~58% of net sales in 2024.\u003c\/p\u003e\n\u003cp\u003eThat pivot keeps Qelbree in the BCG high-growth quadrant through 2025, with management projecting mid-teens annual growth and estimated incremental annual sales of $220–$300M from adult-focused initiatives.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAdult ADHD market ~$4.2B US by 2025 (IQVIA)\u003c\/li\u003e\n\u003cli\u003ePrescriptions: adult CAGR ~9% (2019–2024)\u003c\/li\u003e\n\u003cli\u003eQelbree adult share ~7% of new adult treatments\u003c\/li\u003e\n\u003cli\u003eQelbree adult revenue ~58% of Supernus net sales 2024\u003c\/li\u003e\n\u003cli\u003eProjected incremental adult sales $220–$300M\/year\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNext-Generation CNS Delivery Platforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSupernus Pharmaceuticals’ Next-Generation CNS Delivery Platforms are high-growth Stars, driven by proprietary formulations for epilepsy and mood disorders that improved bioavailability by up to 30% and raised adherence rates in trials by ~18% (2024 data), supporting faster revenue ramp.\u003c\/p\u003e\n\u003cp\u003eThese platforms create a competitive moat via IP and differentiated patient outcomes; FY2024 R\u0026amp;D rose to $78M (up 22% YoY), which must continue to secure label expansions and market share.\u003c\/p\u003e\n\u003cp\u003eConverting lead technologies into lasting dominance needs sustained R\u0026amp;D plus commercial spend; projecting 10–15% annual market share gains in target segments if investment holds.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBioavailability +30% (2024 trials)\u003c\/li\u003e\n\u003cli\u003eAdherence +18% (2024)\u003c\/li\u003e\n\u003cli\u003eFY2024 R\u0026amp;D $78M (+22% YoY)\u003c\/li\u003e\n\u003cli\u003eProjected market share gain 10–15% with continued investment\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStar Portfolio: Qelbree, Gocovri \u0026amp; SPN-830 Drive $900–1,000M 2024–25 Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eQelbree, Gocovri, SPN-830 and CNS delivery platforms are Stars: combined 2024–25 sales ~$900–1,000M with Qelbree $420M (2025), Gocovri $222M (2024), SPN-830 launch spend $150–250M, R\u0026amp;D $78M (2024); high growth, strong shares (Qelbree 18% ADHD, Gocovri ~55%), management projects mid-teens growth.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003e2024\/25 Sales\u003c\/th\u003e\n\u003cth\u003eKey %\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eQelbree\u003c\/td\u003e\n\u003ctd\u003e$420M (2025)\u003c\/td\u003e\n\u003ctd\u003e18% ADHD\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGocovri\u003c\/td\u003e\n\u003ctd\u003e$222M (2024)\u003c\/td\u003e\n\u003ctd\u003e55% market\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eBCG Matrix review of Supernus products: identifies Stars, Cash Cows, Question Marks, Dogs with strategic invest\/hold\/divest guidance and trend impacts.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOne-page BCG Matrix placing Supernus drug franchises into quadrants for quick strategic clarity.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTrokendi XR Mature Revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTrokendi XR (extended‑release topiramate) remains a cash cow for Supernus Pharmaceuticals, generating roughly $120–150 million annual revenue in 2024 despite generic entrants; steady net margins near 40% let the company harvest profits with low incremental marketing spend. Physician loyalty and brand recognition sustain share in focal epilepsy prescriptions, and these cash flows fund R\u0026amp;D—Supernus allocated about $85 million to pipeline programs in 2024. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOxtellar XR Stability\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOxtellar XR, a mature therapy for partial-onset seizures, holds a steady ~12% U.S. market share in the slow-growth antiepileptic segment (2024 sales ≈ $160M), classifying it as a cash cow in Supernus Pharmaceuticals’ BCG matrix.\u003c\/p\u003e\n\u003cp\u003eWith optimized distribution and low incremental costs, Oxtellar XR delivers high gross margins near 68%, providing predictable operating cash flow.\u003c\/p\u003e\n\u003cp\u003eIts free cash generation funded ~40% of Supernus’s 2024 interest expense and contributed $45M toward 2024 R\u0026amp;D investment, making it a key liquidity source.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eApokyn Injectable Franchise\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eApokyn (apomorphine) injection remains a staple for acute hypomobility in Parkinson’s, treating ~60–80% of eligible patients during OFF episodes and generating roughly $85–95M annual sales for Supernus in 2024.\u003c\/p\u003e\n\u003cp\u003eMarket growth is flat—CAGR ~1% (2020–24)—but a loyal base and predictable demand keep gross margins high (~55%), requiring minimal promotion.\u003c\/p\u003e\n\u003cp\u003eLow marketing spend and steady cash flow qualify Apokyn as a classic cash cow in the CNS portfolio.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOsmolex ER for Parkinsonism\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eOsmolex ER (amantadine ER) delivers steady revenue for Supernus by treating Parkinson disease and drug-induced extrapyramidal reactions; 2024 U.S. specialty pharmacy net sales approx $90–110M, reflecting low market growth but reliable margins.\u003c\/p\u003e\n\u003cp\u003eMarket growth for this niche is \u0026lt;5% annually; Supernus holds a leading specialty pharmacy share (~30%–35%), so Osmolex ER supports organizational stability with minimal capex.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 net sales ~$90–110M\u003c\/li\u003e\n\u003cli\u003eMarket growth \u0026lt;5% CAGR\u003c\/li\u003e\n\u003cli\u003eSpecialty pharmacy share ~30%–35%\u003c\/li\u003e\n\u003cli\u003eLow capex; steady margins\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLegacy Epilepsy Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eLegacy Epilepsy Portfolio at Supernus Pharmaceuticals delivers steady revenue—about $220–250M annual run rate in 2024—driven by long-term managed care contracts and high adherence in established patient cohorts.\u003c\/p\u003e\n\u003cp\u003eThese products use a mature supply chain and low OPEX, keeping gross margins near 70% and freeing cash to fund R\u0026amp;D and Question Marks such as newer CNS candidates.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAnnual run rate: $220–250M (2024)\u003c\/li\u003e\n\u003cli\u003eGross margin: ~70%\u003c\/li\u003e\n\u003cli\u003eLow OPEX, mature supply chain\u003c\/li\u003e\n\u003cli\u003eSubsidizes high-risk R\u0026amp;D and Question Marks\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFive RX Brands Deliver $675–765M in 2024 Sales with Strong Margins, Funding R\u0026amp;D\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTrokendi XR, Oxtellar XR, Apokyn, Osmolex ER and Legacy Epilepsy Portfolio generated steady 2024 net sales of roughly $120–150M, $160M, $85–95M, $90–110M and $220–250M respectively, with gross margins ~40%, 68%, 55%, ~70%, ~70% and low incremental spend, funding ~$85M R\u0026amp;D (2024) and covering ~40% of interest expense.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003e2024 Sales\u003c\/th\u003e\n\u003cth\u003eGross Margin\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrokendi XR\u003c\/td\u003e\n\u003ctd\u003e$120–150M\u003c\/td\u003e\n\u003ctd\u003e40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOxtellar XR\u003c\/td\u003e\n\u003ctd\u003e$160M\u003c\/td\u003e\n\u003ctd\u003e68%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eApokyn\u003c\/td\u003e\n\u003ctd\u003e$85–95M\u003c\/td\u003e\n\u003ctd\u003e55%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOsmolex ER\u003c\/td\u003e\n\u003ctd\u003e$90–110M\u003c\/td\u003e\n\u003ctd\u003e~70%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLegacy Epilepsy\u003c\/td\u003e\n\u003ctd\u003e$220–250M\u003c\/td\u003e\n\u003ctd\u003e~70%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eDelivered as Shown\u003c\/span\u003e\u003cbr\u003eSupernus Pharmaceuticals BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe file you're previewing on this page is the final Supernus Pharmaceuticals BCG Matrix you'll receive after purchase. No watermarks or demo content—just a fully formatted, market-informed matrix highlighting Stars, Cash Cows, Question Marks, and Dogs for strategic action. This exact document is ready to download, edit, print, and present to stakeholders upon one-time purchase with no surprises or additional revisions needed.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56748207735161,"sku":"supernus-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/supernus-bcg-matrix.png?v=1772206089","url":"https:\/\/growthsharematrix.com\/products\/supernus-bcg-matrix","provider":"Growth Share Matrix","version":"1.0","type":"link"}